Rising Biosciences (Rising Biosciences) Accounts Payable & Accrued Expense : $0.00 Mil (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Accounts Payable & Accrued Expense?

Rising Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Rising Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Accounts Payable & Accrued Expense Chart

Rising Biosciences Annual Data

Trend

Accounts Payable & Accrued Expense

Rising Biosciences Quarterly Data

Accounts Payable & Accrued Expense

Rising Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.